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Zebraﬁsh have emerged as a powerful model of development and cancer. Human, mouse, and zebraﬁsh malignancies exhibit
striking histopathologic and molecular similarities, underscoring the remarkable conservation of genetic pathways required to
induce cancer. Zebraﬁsh are uniquely suited for large-scale studies in which hundreds of animals can be used to investigate cancer
processes. Moreover, zebraﬁsh are small in size, optically clear during development, and amenable to genetic manipulation. Facile
transgenic approaches and new technologies in gene inactivation have provided much needed genomic resources to interrogate
the function of speciﬁc oncogenic and tumor suppressor pathways in cancer. This manuscript focuses on the unique attribute
of labeling leukemia cells with ﬂuorescent proteins and directly visualizing cancer processes in vivo including tumor growth,
dissemination, and intravasation into the vasculature. We will also discuss the use of ﬂuorescent transgenic approaches and cell
transplantation to assess leukemia-propagating cell frequency and response to chemotherapy.
1. Zebraﬁsh Models of Leukemia
Zebraﬁsh models of hematological malignancies exhibit
striking similarities with human and mouse disease [1–7],
yet aﬀord unique avenues of study due to imaging modalities
thatpermitdirectvisualizationofﬂuorescentlylabeledblood
cells within live animals. As with mouse and human disease,
zebraﬁsh leukemias are distinguished from lymphomas by
the inﬁltration of leukemic cells into the marrow. Lym-
phomas are predominantly located as masses throughout the
body, including lymph nodes in mouse and human, and
have no or little inﬁltration into the marrow [8]. Leukemias
are also classiﬁed as acute or chronic. Acute leukemias are
arrestedatearlystagesofmaturation,arehighlyproliferative,
and advance quickly in patients [8]. By contrast, chronic
leukemias are arrested at later stages of maturation and
resemble functional, yet abnormal, blood cell counterparts.
Although characterized by increased circulating white blood
counts, chronic leukemias are often much slower growing
and take months or years to progress. Leukemias can be
further subdivided based on the blood lineage in which cells
have become transformed [8]. To date, zebraﬁsh models
of Acute Lymphoblastic Leukemias (ALL), Acute Myeloid
Leukemia(AML),andMyeloproliferativeNeoplasms(MPN)
have been described.
Zebraﬁsh ﬁrst emerged as a powerful genetic model of
leukemia with the description of transgenic approaches in
which cMYC was overexpressed in developing thymocytes
[7]. Utilizing the rag2 promoter to drive both MYC and GFP
expression, transgenic zebraﬁsh T-cell acute lymphoblastic
leukemias(T-ALLs)couldbeeasilyvisualizedinliveanimals.
In this model, ﬂuorescently labeled T cell precursors resident
in the thymus were the T-ALL-initiating cell type and dis-
seminated widely over the course of tumor progression [7].2 Advances in Hematology
Moreover, GFP+ thymocytes exhibited stereotypical homing
to the nasal placode, periocular space, and kidney marrow
when assessed by serial ﬂuorescent imaging over days [7].
Subsequent studies developed conditional approaches to
create ﬂuorescent transgenic zebraﬁsh models of T-ALL that
utilized CRE-Lox or tamoxifen-inducible MYC-ER strategies
[5,9].Interestingly,withdrawaloftamoxifenandsubsequent
inactivation of MYC expression led to regression of ﬂuores-
cently labeled T-ALL; however, leukemia regression was not
observed in pten mutant ﬁsh or those that overexpressed
activated Akt [9]. These data indicate that Akt pathway
activation is suﬃcient for tumor maintenance in this model.
Additional studies have utilized ﬂuorescence imaging to
assess synergy between MYC and Bcl2 [5, 10] and NOTCH1-
ICD [1]. Moreover, human NOTCH1-intracellular domain-
EGFP transgene expression induces ﬂuorescently labeled T-
ALL with a long latency of >6 months in mosaic and stable
transgenic zebraﬁsh [6]. Finally, forward genetics screens
that utilize ENU (N-Ethyl-N-nitrosourea-) induced muta-
genesis are easily performed in zebraﬁsh due to their large
clutch size and accessible observation of phenotypes. Utiliz-
ing this approach, the Trede group mutagenized Tg(lck:GFP)
transgenic ﬁsh and visualized animals for ﬂuorescently
labeled T-ALL onset in F1 and F2 animals, identifying both
dominant and recessive mutations that aﬀect T-ALL onset
[11]. Mapping of mutations that are found in these mutant
lines will likely uncover novel mechanisms that drive T-ALL
onset and growth in both zebraﬁsh and man.
Many exciting new models of hematopoietic malignancy
have been created including B-cell acute lymphoblastic leu-
kemia (B-ALL), acute myeloid leukemia (AML), and myelo-
proliferative neoplasm (MPN). For example, Sabaawy et al.
developed a model of B-ALL by overexpressing EGFP-TEL-
AML1 from a ubiquitous transgene promoter. In this model,
16 of 545 transgenic animals developed B-ALL by 8–12
months of age [2]. Zhuravleva et al. generated transgenic
zebraﬁsh in which the MYST3/NCOA2 fusion gene was
expressed under control of the spi1 promoter [12]. 2 of 180
MYST3/NCOA2-EGFP mosaic transgenic animals developed
AML at 14 and 26 months. Two models of MPN have also
been developed. Le et al. utilized CRE/Lox techniques to
conditionally activate kRASG12D in developing embryos
[3]. A subset of these animals went on to develop myelo-
proliferative neoplasm with a latency of 66.2 ± 23.1 days
(n = 10 of 19 ﬁsh). Forrester et al. also developed a condi-
tional CRE/Lox transgenic approach to model MPN [13].
Speciﬁcally, NUP98-HOXA9 was conditionally activated in
pu.1 expressing cells, leading to 23% of adult NUP98-
HOXA9-transgenic ﬁsh developing MPN by 19–23 months
of age. Finally, several investigators have utilized heat-shock
transgenicapproachestouncoverearlydevelopmentaleﬀects
offusiononcogenesinblooddevelopment,includingAML1-
ETO, RUNX1-CBF2T1, and TEL-JAK2 [4, 14, 15]. These
heat-shock approaches drive transgene expression during
early development and often result in aberrant arrest of cells
in early stages of blood development. However, the devel-
opmentoffrankleukemiainheat-shockinducibletransgenic
lines has yet to be reported. Taken together, zebraﬁsh have
fast emerged as a novel animal model of leukemia and are
poised to contribute to our understanding of the molecular
pathogenesis of human disease.
2. Fluorescent Transgenic Approachesto
LabelLeukemiaCells
Many studies have employed the use of stable transgenic
zebraﬁsh to drive oncogenic transgene expression in a tissue-
speciﬁc manner including pancreatic adenocarcinoma [16],
hepatocellular carcinoma [17], melanoma [18–20], embry-
onal rhabdomyosarcoma [21], and leukemia. By and large,
investigators have used oncogene fusions with GFP to
create tumors that are ﬂuorescently labeled. For example,
we and others have generated EGFP-Myc, NOTCH1-
GFP, EGFP-TEL-AML1,a n dMYST3/NCOA2-EGFP fusions
to drive leukemogenesis while also ﬂuorescently labeling
leukemic cells [2, 6, 7, 12]. Although these approaches have
been largely successful in generating ﬂuorescently labeled
leukemias, it is worth noting that ﬂuorescent protein expres-
sion is linked with oncogene localization within the cell and
proteinstability.Forexample,MYCisanucleartranscription
factor with a half-life of ∼30 minutes in non-transformed
cells. Thus, the EGFP-MYC fusion protein is rapidly turned
over in normal thymocytes prior to GFP maturation into
a functional ﬂuorescent molecule, precluding the use of
ﬂuorescencetoidentifystabletransgenicTg(rag2:EGFP-Myc)
animals at 5 days of life. However, the EGFP-Myc trans-
gene is stabilized following transformation leading to weak,
nuclear ﬂuorescent protein expression in T-ALL. Fluores-
cent protein fusions can also exhibit reduced transforming
activity depending on cellular context. For example, we
have developed a zebraﬁsh model of kRASG12D-induced
embryonal rhabdomyosarcoma but have been unable to
model this disease using the same transgene promoter to
drive expression of a GFP fusion with kRASG12D. By
contrast, others have used similar RAS fusion constructs
to generate ﬂuorescently labeled hepatocellular carcinoma,
pancreatic adenocarcinoma, and melanoma [16, 17, 19, 20].
To obviate issues surrounding the function of ﬂuorescent
protein-oncogene fusions, it is possible to utilize dual
transgenic approaches to drive both the oncogene and
ﬂuorescent protein within the same cell types. For example,
Tg(rag2:Myc) lines could be bred to Tg(rag2:GFP) ﬁsh. The
resulting progeny would develop T-ALL that expresses high
ﬂuorescent protein expression.
Although stable transgenic zebraﬁsh have been used to
develop robust models of cancer, mosaic transgenic ap-
proaches provide many unique beneﬁts for modeling cancer
in zebraﬁsh. First, stable transgenic zebraﬁsh are often prone
to developing early onset cancers, making maintenance of
stable lines diﬃcult. Second, the creation of stable transgenic
zebraﬁsh is time-consuming and requires crossing putative
transgenic animals to identify founder ﬁsh. Although the
transgenesiswithTol2transposasehasfacilitatedthecreation
of stable transgenic lines, complex breeding strategies are
required to introduce additional transgenes and/or mutant
alleles into a given background. Such approaches often
require multiple generations to develop strains of interest.
By contrast, mosaic transgenesis relies on the ability ofAdvances in Hematology 3
multiple, linearized transgenes to incorporate into the ge-
nome as concatamers when microinjected into one-cell stage
zebraﬁsh, ultimately culminating in the coexpression of
transgenes in developing disease. We have successfully used
this approach to show that kRASG12D collaborates with p53
loss to induce early onset embryonal rhabdomyosarcoma
[22] and work from Feng et al., elegantly showed that
mosaic transgenesis can be used to modify Myc-induced
T-ALL through coinjection of activated Akt [10]. We have
used similar approaches to develop T-ALLs that coexpress
MYC and various ﬂuorescent reporters including AmCyan,
GFP, zsYellow, dsREDexpress, and mCherry [23, 24]. In
these experiments, embryos are coinjected with Myc and
ﬂuorescent protein under transcriptional control of the rag2
promoter. A small cohort of animals develop ﬂuorescently
labeled thymi that eventually progresses into T-ALL. Using
t h i sa p p r o a c h ,w eh a v eb e e na b l et oc r e a t eT - A L L si nv a r i o u s
genetic backgrounds, permitting the creation of syngeneic
strain ﬁsh that develop multicolored T-ALL (Figure 1)[ 23].
Finally, we have recently utilized mosaic transgenesis to
coexpress Notch1a-ICD, MYC, and GFP by coinjection of
three transgenes simultaneously into one-cell stage ani-
mals [1]. In summary, while some ﬂuorescent transgenic
approaches can be limited by fusion stability, early onset of
cancer, and genetic background, other ﬂuorescent transgenic
approaches have been able to overcome these limitations.
Such approaches provide rapid assays to identify collaborat-
ing oncogenic/tumor suppressor pathways in leukemia.
3. CellTransplantationApproachesto
VisualizeTumor Cell Engraftment
Investigators have utilized cell transplantation of ﬂuores-
cently labeled cancer cells into sublethally irradiated adult
zebraﬁsh to assess tumorigenicity [7]. For example, Traver et
al.optimizedcelltransplantationofbothbloodandleukemic
cells into gamma-irradiated animals [7, 25]. Speciﬁcally,
recipient ﬁsh were irradiated with 20–25Gy two days prior
to cell transplantation and then injected with ﬂuorescently
labeleddonorcellsintotheperitonealcavityorsinusvenosis.
For T-ALL, animals can be injected with 1 × 106 cells and
assessed for ﬂuorescently labeled leukemia engraftment at 10
daysposttransplantation[7,25].Imagingofengraftmentcan
be further facilitated by transplantation into optically clear
strains of zebraﬁsh that lack iridiphores and melanocytes—
aptlynamedcasper [26].Casper ﬁshwerecreatedbybreeding
together roy and nacre mutants and must be maintained
as double homozygous mutant animals. These ﬁsh are
transparent as adults, facilitating detailed imaging of cell
migration, metastasis, and kinetics of tumor growth. For
example, recent work has shown that blood cells can be
tracked and counted within the circulation of live adult ﬁsh
using an integrated optical system that combines a laser
scanning confocal microscope and an in vivo ﬂow cytometer
[27].
Although transplantation of donor cells into irradiated
recipients is apowerful tool toassessshort-termengraftment
potential, long-termengraftmentofcells >20daysposttrans-
plantation is often not possible due to the recovery of the
hostimmune systemandsubsequentattackofengraftedcells
[23, 28]. To avoid immune rejection, Mizgirev and Revskoy
recently developed syngeneic zebraﬁsh strains and created
robust models of transplantable, chemically induced hepato-
cellular carcinomas, hepatoblastomas, cholangiocarcinoma,
and pancreatic carcinoma [29–31]. Speciﬁcally, syngeneic
zebraﬁshwerecreatedbyfertilizingeggswithUV-inactivated
sperm,thensubjectingeggstoheat-shock[29].Femalegyno-
genic diploid animals were raised to adulthood and the pro-
cess repeated. The resulting progeny were genetically similar
and could be maintained by incrossing or mating male ﬁsh
backtothefoundingmother.Severallineswerecreatedusing
this method including clonal golden strain 1 and 2 (CG1
and CG2). Adoptive transfer of chemical-induced cancers
and Tg(rag2:EGFP-Myc-) induced T-ALLs from CG2-strain
ﬁsh could engraft disease into syngeneic recipients [31].
Moreover, ﬂuorescently labeled rhabdomyosarcoma and T-
ALL cells arising in CG1 strain ﬁsh could also engraft into
nonirradiated, recipient ﬁsh [23, 24]. Taken together, these
results illustrate the power of cell transplantation and use of
syngeneic zebraﬁsh to study leukemia cell engraftment.
4. CellTransplantationApproachesto
ExamineTumor CellHomingand
IntravasationintoVessels
Blood cells and their dynamic cell movements can be eas-
ily visualized in live ﬂuorescent transgenic zebraﬁsh. For
example, researchers have tracked the migration of various
blood lineages including erythroid and macrophage pro-
genitors [25, 32–34]. Importantly, hematopoietic stem cell
(HSC) movement can also be followed in Tg(CD41:eGFP),
Tg(cmyb:GFP), Tg(runx1:GFP), and Tg(lmo2:GFP) trans-
genic zebraﬁsh larvae [35–40]. Moreover, ﬂuorescently
labeled blood cells can also be tracked in adult ﬁsh [27,
41]. Capitalizing on cell transplantation approaches, inves-
tigators have also utilized ﬂuorescence imaging to visualize
normal hematopoietic cell homing in live animals. For
example, Bertrand et al. visualized HSC homing to the
caudalhematopoietictissuebytransplantingTg(CD41:eGFP;
gata1:dsRed) cells into irradiated recipients [36]. We have
alsodescribedthehomingofTg(lck:GFP)+Tcellsbacktothe
thymusfollowingtransplantationofcellsintolarvalwildtype
ﬁsh [42]. While malignant GFP+ T-ALL lymphoblasts also
migrate to the thymus, they exhibit robust and speciﬁc
homing to the olfactory bulb [6, 7] .T h e s es t u d i e sd e m o n -
strate the ease of visualizing cell migration and homing to
speciﬁc anatomically deﬁned sites within live animals using
ﬂuorescently labeled normal hematopoietic and leukemic
cells.
Intravasation of cancer cells into the vasculature is a crit-
ical step in cancer progression, allowing the spread of tumor
cells beyond the site of origin [43]. The extent to which
lymphoblasts disseminate is the clinically deﬁning charac-
teristic of T-lymphoblastic lymphoma (T-LBL) and acute T-
lymphoblastic leukemia (T-ALL) [8]. In T-LBL, transformed
lymphoblastsareconﬁnedtomediastinalmasses,whilefrank
leukemia involves dissemination of cells to the marrow.4 Advances in Hematology
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Figure 1: Fluorescently labeled Myc-induced T-ALLs from CG1-strain zebraﬁsh engraft into nonirradiated CG1-strain recipients. (a)–(c)
GFP-labeled T-ALLs were isolated from primary leukemic ﬁsh, and 1 × 103 FACS sorted GFP-labeled leukemia cells were transplanted
into nonirradiated CG1-strain animals and scored for engraftment at 10, 20, and 30 days posttransplantation. (d)–(f) T-ALL transplant
recipients that express Amcyan (d), dsRED (e), and zsYellow (f) under the rag2 promoter. Panels are merged images of ﬂuorescent and
brightﬁeld photographs. Images were originally published in [23].
Remarkably, this disease transition was recently visualized
in zebraﬁsh transplanted with ﬂuorescently labeled lym-
phoblasts [10]. For example, RFP+ lymphoblasts from Myc-
induced T-ALL were able to intravasate into Tg(ﬂi:GFP)-
labeled vasculature, while cells that overexpressed the anti-
apoptotic protein Bcl2 were unable to enter the vasculature
and, thus, were arrested in a T-LBL state (Figure 2)[ 10].
Remarkably, treatment of transgenic zebraﬁsh that overex-
pressed MYC and Bcl2 with an antagonist to Sphingosine-1-
Phosphate (S1P1), a T-cell adhesion and migration protein,
promoted invasion into the vasculature [10]. These elegant
studies by Feng et al. were the ﬁrst to directly visualize the
molecular mechanisms governing the transition of T-LBL
to T-ALL and underscore the power of imaging dynamic
cellular processes in ﬂuorescently labeled animals.
5. Fluorescence Imagingto Visualize
Leukemia Responses to Drug Treatment
andGamma-Irradiation
Fluorescence imaging of transplanted cancer cells can also
be used to visualize response to chemotherapy and radi-
ation. For example, the Revskoy group recently showed
that GFP-labeled T-ALL cells could be serially transplanted
into syngeneic strain larvae [31]. Treatment of transplant
recipients with vincristine or cyclophosphamide reduced
tumor burden (Figure 3) and extended lifespan signiﬁcantly
[31]. These experiments established that high-throughput
cell transplantation assays can generate large cohorts of
animals for drug screens and showed that zebraﬁsh T-ALL
responds to the same drugs that are used to treat human T-
ALL patients [31]. In addition, ﬂuorescently labeled cells can
be assessed for response to radiation. For example, we have
shown that engrafted GFP-labeled T-ALLs that coexpress
EGFP-bcl2andtheMyc transgenefailedtoundergoapoptosis
following20Gyofgamma-irradiation[44];however,T-ALLs
that express only Myc were ablated by 4 days postirradiation,
suggesting that Myc-induced T-ALL have an intact p53 DNA
damage pathway.
6. CellTransplantationApproachesto
QuantifyLeukemia PropagatingCell
Frequencyand Aggression
Leukemia-propagating cells (LPCs) have the capacity to pro-
duce all the other cell types contained within the leukemia,
are responsible for continued tumor growth, and ultimately
drive relapse. Investigators have used ﬂuorescence-activated
cell sorting (FACS) to identify unique cell populations and
limiting dilution cell transplantation to assess if molecularly
deﬁned leukemia cells retain LPC activity in human disease.
For example, in AML a rare CD34+, CD38− cell enriches
for leukemia-propagating potential [45, 46]. In T-ALL, it
has been suggested that CD34+ CD7+ cell populations are
enriched in LPCs [47]. Despite enormous eﬀorts aimed
at deﬁning if and what cell surface markers deﬁne LPC
activity, relatively little is known about the molecular
mechanisms that drive leukemia propagating activity. For
example, elegant work from Jean Soulier’s group has shown
xenograft transplantation of primary human T-ALL intoAdvances in Hematology 5
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Figure 2: Zebraﬁsh T-lymphoblasts overexpressing bcl2 spread locally but fail to intravasate into vasculature. (a)–(c) dsRED2-expressing
lymphoma cells (b) from the Myc; Cre ﬁsh intravasate into EGFP-labeled vasculature (a) of the transplant host Tg(ﬂi1:EGFP); Casper by 6
days posttransplantation (see arrowheads in (c)). (d)–(f) In contrast, dsRED2-expressing lymphoma cells (e) from the Myc; Cre; bcl2 ﬁsh fail
to intravasate vasculature (d) of the transplant hosts by 6 days posttransplantation (compare (f) with (c)). Note aggregates of the Myc; Cre;
bcl2 lymphoma cells in (e) and (f). Scale bar is 10µm. Reprinted from [10].
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Figure 3: Syngeneic zebraﬁsh transplant models of T-ALL are a powerful tool for drug discovery: T-ALL growth is suppressed by
cyclophosphamide treatment. Approximately 200 cells/5nL were engrafted into 5-day-old syngeneic CG2 larvae. Engrafted animals were
treated with cyclophosphamide (400mg/L dissolved in ﬁsh water) beginning 5 days posttransplantation. Images of control (a) and treated
animals.(b)Tumorgrowth wasassessedbased onthepercentage ofbodytakenover byGFP+T-ALLandcompared using t-testcalculations.
This work was performed in [31] and later published in [61].
immune-compromised mice selected for a small subset of
clones found within the diagnosis leukemia [48]. These
clones contained speciﬁc genomic lesions that likely increase
leukemia aggression and increase the frequency of LPCs
within the bulk of the leukemia mass [48]. Yet, despite
the identiﬁcation of recurrent genomic changes associated
within continued clonal evolution, the mechanisms driving
these relapse-associated processes are largely unknown.
The processby whichleukemic cellsacquiremutations to
increase aggression and frequency of LPCs has been diﬃcult
to study in human and mouse models of disease. However,
recent work from the Trede group has utilized serially
passaged ﬂuorescently labeled zebraﬁsh T-ALLs to demon-
strate that leukemias become more aggressive and develop
with shortened latency [49]. To assess genetic changes
acquired between the primary and evolved clones, array
comparativehybridizationstudieswerecompletedtoidentify
recurrentgenomicDNAalterationsassociatedwithincreased
aggression. An average of 34 new copy number aberrations
(CNAs) were identiﬁed in T-ALLs following serial passaging,
a majority of which were also found in human T-ALL [49].
Clonal evolution can also result in increased numbers of
LPCs contained within the leukemia mass [48]. To directly
assess LPC frequency within the bulk of the tumor mass,
we have pioneered high-throughput limiting dilution cell
transplantation approaches and showed that 1% of Myc-
induced T-ALL cells has the capacity to remake leukemia
in syngeneic recipient animals [23, 24]. Following serial
passaging, a subset of clones can increase LPC activity with
up to 16% of cells now capable of inducing leukemia in
transplant recipient animals [23]. Similar array CGH studies
as described by Rudner et al. [49] are currently underway6 Advances in Hematology
to identify recurrent CNAs associated with modulating LPC
frequencyinzebraﬁshT-ALL.Takentogether,webelievethat
unbiased genetic approaches, when coupled with limiting
dilution cell transplantation assays in zebraﬁsh, will likely
uncover the mechanisms driving relapse-associated changes
in aggression and LPC frequency in human disease.
7. Conclusion and Challenges for the Future
Zebraﬁsh has fast emerged as a powerful model of leukemia.
When coupled with ﬂuorescent transgenic approaches and
powerful imaging techniques, these models are uniquely
positioned to uncover mechanisms driving tumor dissem-
ination, progression, and relapse. Moreover, the use of
multiﬂuorescent transgenic animals will allow for labeling of
tumor cell compartments similar to those deﬁned in RAS-
induced rhabdomyosarcoma models [21, 50] and for the
visualizing of leukemia growth in relation to supportive cell
types including vasculature, ﬁbroblasts, and macrophages.
Moreover, though not the focus of this paper, cell transplan-
tation approaches that utilize ﬂuorescently labeled, human
leukemia cells into either zebraﬁsh embryos or adults will
likely provide novel experimental models to assess tumor
growth and response to therapy [51–60], capitalizing on the
numbers of disease animals that can be created by micro-
injection and direct visualization of tumor growth in vivo.
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